Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2023-N-3549]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 35 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of October 5, 2023.
 FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137, 
                        *Kimberly.Lehrfeld@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Application No.
Drug
ApplicantNDA 001546
Guanidine (guanidine hydrochloride (HCl)) Tablets, 125 milligrams (mg)
Merck Sharp & Dohme LLC, 126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ 07065.NDA 010841
Peganone (ethotoin) Tablets, 250 mg and 500 mg
Recordati Rare Diseases Inc., 100 Corporate Dr., Lebanon, NJ 08833.NDA 016801
Xylocaine Preservative Free (lidocaine HCl) Injection, 1%, 2%, 4%, 10%, and 20%
Fresenius Kabi USA, LLC, 3 Corporate Dr., Lake Zurich, IL 60047.NDA 016822
FreAmine 8.5% (amino acids) Injection, 8.5 grams (g)/100 milliliters (mL)
B. Braun Medical Inc., 901 Marcon Blvd., Allentown, PA 18109.FreAmine HBC 6.9% (amino acids) Injection, 6.9 g/100 mLFreAmine II 8.5% (amino acids) Injection, 8.5 g/100 mLFreAmine III 10% (amino acids) Injection, 10 g/100 mLFreAmine III 8.5% (amino acids) Injection, 8.5 g/100 mLFreAmine III 8.5% with electrolytes (amino acids, magnesium acetate, phosphoric acid, potassium acetate, potassium chloride, sodium acetate) Injection, 8.5%; 110mg/100mL; 230mg/100mL; 10mg/100mL; 440mg/100mL; 690mg/100mLFreAmine III 3% with electrolytes (amino acids, magnesium acetate, phosphoric acid, potassium chloride, sodium acetate, sodium chloride) Injection, 3%; 54mg/100mL; 40mg/100mL; 150mg/100mL; 200mg/100mL; 120mg/100mLNDA 017407
Catapres (clonidine HCl) Tablets, 0.1 mg, 0.2 mg, and 0.3 mg
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, CT 06877.NDA 017425
Proglycem (diazoxide) Capsules, 50 mg and 100 mg
Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Pkwy., West Chester, PA 19380.NDA 017534
Fiorinal (aspirin, butalbital, caffeine) Capsules, 325 mg/50 mg/40 mg
AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064.Fiorinal (aspirin, butalbital, caffeine) Tablets, 325 mg/50 mg/40 mgNDA 018582
Procalamine (amino acids, calcium acetate, glycerin, magnesium acetate, phosphoric acid, potassium chloride, sodium acetate, sodium chloride) Injection, 3%; 26mg/100mL; 3g/100mL; 54mg/100mL; 41mg/100mL; 150mg/100mL; 200mg/100mL; 120mg/100mL
B. Braun Medical Inc.NDA 018676
HepatAmine 8% (amino acids) Injection, 8g/100mL
Do.NDA 018878
Indocin (indomethacin sodium) Injection, equivalent to (EQ) 1 mg base/vial
Recordati Rare Diseases Inc.( print page 60691)NDA 019099
Dopamine HCl and Dextrose 5% Injection, 80 mg/100 mL and 320 mg/100 mL
                             Dopamine HCl and Dextrose 5% in plastic container Injection, 40 mg/100 mL and 160 mg/100 mL
B. Braun Medical Inc.NDA 019111
Tussionex Pennkinetic (chlorpheniramine polistirex, hydrocodone polistirex) Extended-Release Suspension, EQ 8 mg maleate/5 mL; EQ 10 mg bitartrate/5 mL
UCB Inc., 1950 Lake Park Dr., Building 2100, Smyrna, GA 30080.NDA 019429
Fiorinal with Codeine (aspirin, butalbital, caffeine, codeine phosphate) Capsules, 325 mg/50 mg/40 mg/30 mg
AbbVie Inc.NDA 019898
Pravachol (pravastatin sodium) Tablets, 10 mg, 20 mg, 40 mg, and 80 mg
Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543.NDA 020281
Ultram (tramadol HCl) Tablets, 50 mg and 100 mg
Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Rd., Titusville, NJ 08560.NDA 020381
Niaspan (niacin) Extended-Release Tablets, 375 mg, 500 mg, 750 mg, and 1 g
AbbVie Inc.Niaspan Titration Starter Pack (niacin) Extended-Release Tablets, 375 mg, 500 mg, and 750 mgNDA 020544
Jadelle (levonorgestrel) Implants for Subdermal Use, 75 mg/implant
Population Council, 1230 York Ave., New York, NY 10065.NDA 020616
Kadian (morphine sulfate) Extended-Release Capsules, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 130 mg, 150 mg, and 200 mg
AbbVie Inc.NDA 020636
Viramune (nevirapine) Tablets, 200 mg
Boehringer Ingelheim Pharmaceuticals, Inc.NDA 021065
Femhrt (ethinyl estradiol, norethindrone acetate) Tablets, 0.0025 mg/0.5 mg and 0.005 mg/1 mg
Allergan Pharmaceuticals International Limited c/o AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064.NDA 021066
Zaditor (ketotifen fumarate) Ophthalmic Solution, EQ 0.025% base
Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX 76134.NDA 021123
Ultracet (acetaminophen, tramadol HCl) Tablets, 325 mg/37.5 mg
Janssen Pharmaceuticals, Inc.NDA 021513
Enablex (darifenacin hydrobromide) Extended-Release Tablets, EQ 7.5 mg base and EQ 15 mg base
AbbVie Inc.NDA 021615
Razadyne ER (galantamine hydrobromide) Extended-Release Capsules, EQ 8 mg base, EQ 16 mg base, and EQ 24 mg base
Janssen Research and Development, LLC, 1125 Trenton-Harbourton Rd., Titusville, NJ 08560.NDA 021790
Dacogen (decitabine) Injection, 50 mg/vial
Otsuka Pharmaceutical Co., Ltd., c/o Otsuka Pharmaceutical Development and Commercialization, Inc., 2440 Research Blvd., Rockville, MD 20850.NDA 021830
Asacol HD (mesalamine) Delayed-Release Tablets, 800 mg
AbbVie Inc.NDA 021844
Desonate (desonide) Gel, 0.05%
LEO Pharma A/S, c/o LEO Pharma Inc., 7 Giralda Farms, Madison, NJ 07940.NDA 022292
Aptivus (tipranavir) Oral Solution, 100 mg/mL
Boehringer Ingelheim Pharmaceuticals, Inc.NDA 022439
Zutripro (chlorpheniramine maleate, hydrocodone bitartrate, pseudoephedrine HCl) Oral Solution, 4 mg/5 mL; 5 mg/5 mL; 60 mg/5 mL
Persion Pharmaceuticals LLC, 10 North Park Place, Suite 201, Morristown, NJ 07960.NDA 022442
Rezira (hydrocodone bitartrate, pseudoephedrine HCl) Oral Solution, 5 mg/5 mL; 60 mg/5 mL
Do.NDA 204307
Vituz (chlorpheniramine maleate, hydrocodone bitartrate) Oral Solution, 4 mg/5 mL; 5 mg/5 mL
Do.NDA 204768
Tivorbex (indomethacin) Capsules, 20 mg and 40 mg
Genus Lifesciences Inc., 514 North 12th St., Allentown, PA 18102.NDA 206619
Viekira Pak (dasabuvir sodium; ombitasvir, paritaprevir, ritonavir) Tablets, EQ 250 mg base; 12.5 mg/75 mg/50 mg
AbbVie Inc.NDA 208374
Bivalirudin in 0.9% Sodium Chloride Intravenous Solution, 250 mg/50 mL and 500 mg/100 mL
Baxter Healthcare Corp., 1 Baxter Pkwy., Deerfield, IL 60015.NDA 210583
Anjeso (meloxicam) Intravenous Solution, 30 mg/mL
Baudax Bio, Inc., 490 Lapp Rd., Malvern, PA 19355.
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of October 5, 2023. Approval of each entire application is withdrawn, including any strengths and dosage forms included in the application but inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products listed in the table without approved new drug applications violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)). Drug products that are listed in the table that are in inventory on October 5, 2023 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: August 29, 2023. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2023-19013 Filed 9-1-23; 8:45 am] BILLING CODE 4164-01-P